AVROBIO, Inc. Profile Avatar - Palmy Investing

AVROBIO, Inc.

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modif…

Biotechnology
US, Cambridge [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of AVRO's Analysis
CIK: 1681087 CUSIP: 05455M100 ISIN: US05455M1009 LEI: - UEI: -
Secondary Listings
AVRO has no secondary listings inside our databases.